1. Introduction {#sec1-jcm-09-02668}
===============

Major Depression (MD) and alcohol use disorders (AUD) are two of the more prevalent mental health disorders in the general population and constitute a major health burden worldwide \[[@B1-jcm-09-02668],[@B2-jcm-09-02668]\]. Clinical \[[@B3-jcm-09-02668],[@B4-jcm-09-02668],[@B5-jcm-09-02668],[@B6-jcm-09-02668],[@B7-jcm-09-02668]\] and epidemiological \[[@B8-jcm-09-02668],[@B9-jcm-09-02668],[@B10-jcm-09-02668],[@B11-jcm-09-02668],[@B12-jcm-09-02668]\] studies show that MD and Alcohol Use Disorder (AUD) frequently co-occur. A systematic review of longitudinal or cross-sectional epidemiological studies found that the presence of either disorder doubled the risk of the second disorder \[[@B13-jcm-09-02668]\], meaning that patients with MD are twice as likely to develop an AUD and vice versa \[[@B14-jcm-09-02668]\].

Diagnosis and treatment of the commonly co-occurring AUD and depressive disorders implies many challenges \[[@B15-jcm-09-02668]\]. Diagnosis is particularly challenging because, as described in other substances with addiction liability, the acute and chronic effects related to alcohol consumption/withdrawal can mimic depressive symptoms. In this sense, MD associated to any SUD has been recognized by both, DSM and ICD classifications for a long time (DSM-IV, IV-TR and DSM-5; ICD-10, ICD-11). The need to differentiate between primary and substance-induced mood disorders has been long-established due to their prevalence and important treatment implications (see systematic reviews published by Schuckit in 2006, Nunes and Levin 2004, Torrens et al., 2005) \[[@B16-jcm-09-02668],[@B17-jcm-09-02668],[@B18-jcm-09-02668]\]. In particular, the differentiation among independent depression or alcohol-induced depression has been extensively studied in terms of characteristics, prognosis, suicide risk and relapse risk among others \[[@B11-jcm-09-02668],[@B13-jcm-09-02668],[@B19-jcm-09-02668],[@B20-jcm-09-02668],[@B21-jcm-09-02668],[@B22-jcm-09-02668],[@B23-jcm-09-02668],[@B24-jcm-09-02668],[@B25-jcm-09-02668],[@B26-jcm-09-02668]\]. Given the available knowledge, it can thus be stated that induced depressive episodes can be as or more serious than primary or independent ones, both in terms of relapse to substance use \[[@B3-jcm-09-02668],[@B27-jcm-09-02668]\] and in the severity of depressive symptomatology \[[@B21-jcm-09-02668],[@B28-jcm-09-02668]\], including risk of suicide \[[@B19-jcm-09-02668],[@B22-jcm-09-02668]\]. This difference may be especially relevant for treatment management \[[@B18-jcm-09-02668],[@B23-jcm-09-02668]\]. In the case of alcohol, each type of depressive episode could be considered as two different diseases since Primary MD patients' present greater familial risk to develop a primary episode, while this association is not present for the induced episodes \[[@B29-jcm-09-02668]\].

It is has been enough established that depressed patients exhibited elevated levels of C Reactive Protein (CRP) and a significant decrease in their Thyroid-stimulating hormone (TSH) levels, directly related with hypothyroidism \[[@B30-jcm-09-02668],[@B31-jcm-09-02668]\]. Alcohol abuse is a major cause of abnormal liver function and liver enzyme activities are important screening tools for detecting liver disease \[[@B32-jcm-09-02668]\]. Other biomarkers such as cholesterol and triglycerides were previously associated with depression and alcohol use disorder. Although with controversial results, metabolic syndrome, especially lipid dysregulation have been found in primary depression \[[@B33-jcm-09-02668],[@B34-jcm-09-02668]\]; furthermore, alcohol consumption has been related with a tendency towards hypertriglyceridemia \[[@B35-jcm-09-02668]\].

Furthermore, MD and AUD are complex disorders which encompass multiple genetic and environmental factors \[[@B30-jcm-09-02668]\]. Both AUD and MD have substantial genetic contributions with heritability estimates of 50--60% for AUD \[[@B31-jcm-09-02668]\] and 30--40% for MD \[[@B32-jcm-09-02668]\]. Increased familial recurrence risk and heritability have been associated with earlier-onset and recurrent depression \[[@B33-jcm-09-02668],[@B34-jcm-09-02668],[@B35-jcm-09-02668]\] as well as greater depression severity or impairment \[[@B36-jcm-09-02668],[@B37-jcm-09-02668]\].

Common genetic factors that influence the co-occurrence of MD and AUD have been sought in family, twin, and adoption studies \[[@B36-jcm-09-02668],[@B37-jcm-09-02668],[@B38-jcm-09-02668],[@B39-jcm-09-02668],[@B40-jcm-09-02668],[@B41-jcm-09-02668],[@B42-jcm-09-02668],[@B43-jcm-09-02668]\]. GWASs have reported genome-wide significant findings for AUD \[[@B44-jcm-09-02668],[@B45-jcm-09-02668]\] and MD \[[@B46-jcm-09-02668],[@B47-jcm-09-02668],[@B48-jcm-09-02668],[@B49-jcm-09-02668],[@B50-jcm-09-02668]\]. However, no consistent findings have been reported for comorbid AUD and MD \[[@B51-jcm-09-02668],[@B52-jcm-09-02668]\]. Discovering the genetic component of shared liability presents an opportunity to clarify the aetiology of both disorders \[[@B51-jcm-09-02668]\]. Evidence suggests that genetic influences underlying psychiatric and substance use disorders might differ across ancestry groups. In a recent report from Zhou et al. \[[@B52-jcm-09-02668]\], a single genome-wide significant variant was detected, located in the SEMA3A gene. The variant was only common enough to be tested in the African American sample; however, nearby variants in the European American sample that occurred with sufficient frequency to test showed no evidence of association \[[@B52-jcm-09-02668]\].

Given the high prevalence and related negative impact of the comorbidity between AUD and Induced Major Depressions (I-MD), the need to distinguish between co-morbid conditions (i.e., independent psychiatric problems) and conditions where psychiatric symptoms are secondary to substance use has become crucial for clinicians working with substance use disorder patients. As far as we know, there are no studies that characterize Induced Major Depressions (I-MD) from a clinical ad biological perspective to differentiate them from Primary Major Depression (Primary MD). The objective of the present study was to investigate clinical, biological and genetic differences between Primary MD and AI-MD.

2. Material and Methods {#sec2-jcm-09-02668}
=======================

2.1. Design {#sec2dot1-jcm-09-02668}
-----------

This is a cross-sectional study comparing two different phenotypes of MD: The Primary MD and the AI-MD.

2.2. Participants and Recruitment {#sec2dot2-jcm-09-02668}
---------------------------------

From November 2015 to October 2017, a total of 111 patients were assessed for eligibility. Participants were recruited from detoxification, dual diagnosis and acute psychiatric units from the Neuropsychiatry and Addiction Institute of Parc de Salut Mar in Barcelona (PSMAR). Both Primary MD and AI-MD diagnoses were done according to DSM-IV-TR criteria \[[@B53-jcm-09-02668]\]. Inclusion criteria included both genders, aged between 18 and 65 years and of Caucasian origin. Exclusion criteria for both groups were: language barrier or intellectual difficulties that limited the understanding of evaluations, history of pathological conditions or any kind of somatic disorder or disease that the investigator considered unsuitable for the study, other concomitant psychiatric disorder in axis I and any diagnosis of substance use disorder (current or life-time, except nicotine use disorder) (DSM-IV-TR) in the MD group; in the AI-MD group, any other diagnosis of substance use disorder than alcohol use disorder or nicotine use disorder (DSM-IV-TR). Participants from the AI-MD group recruited in the detoxification unit were included in the study at the end of their admission (mean days of admission 13); all of them were under pharmacological treatment of their alcohol abstinence syndrome and also, all participants had punctuations in the Revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar) below 10 at the inclusion.

2.3. Measures {#sec2dot3-jcm-09-02668}
-------------

### 2.3.1. Clinical Assessments {#sec2dot3dot1-jcm-09-02668}

Participants were evaluated using the Spanish version of the Psychiatric Research Interview for Substance and Mental Diseases (PRISM) \[[@B54-jcm-09-02668],[@B55-jcm-09-02668]\] according to "Diagnostic and Statistical Manual of Mental Disorders-4th Edition-Text Revision" (DSM-IV-TR) criteria \[[@B53-jcm-09-02668]\], including a protocol of a family history of depression. In addition, the validated Spanish version of the following instruments were used: severity of depression was assessed using the Spanish validated version of the "Hamilton Depression rating Scale (HAM-D)" \[[@B56-jcm-09-02668]\], the Spanish validated version of the "Beck Depression Inventory (BDI)" \[[@B57-jcm-09-02668]\] and the Spanish validated version of the "Scale for Suicide Ideation (SSI)" \[[@B58-jcm-09-02668]\]. Anxiety severity was evaluated with the Spanish validated version of the "Hamilton Anxiety rating Scale (HAM-A)" \[[@B59-jcm-09-02668]\] and the Spanish validated version of "State-Trait Anxiety Inventory (STAI-R)" \[[@B60-jcm-09-02668]\]. Personality was assessed with the Spanish validated version of the "Temperament and Character Inventory (TCI)" of Cloninger \[[@B61-jcm-09-02668]\]. Traumatic and stressful life events were evaluated with the Spanish validated version of the "Life Stressor Checklist-Revised" (LSC-R) \[[@B62-jcm-09-02668]\].

### 2.3.2. Blood Samples {#sec2dot3dot2-jcm-09-02668}

A total of 20 mL of blood sample was collected from each participant. From the total, 10 mL was used to conduct a blood test, assessing the levels of C Reactive Protein (CRP), Thyroid-stimulating hormone (TSH), liver function (bilirubin, alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transpeptidase (GGT)) and lipids (triglycerides and cholesterol). The other 10mL of blood sample was collected to perform the GWAS analysis.

2.4. Procedure {#sec2dot4-jcm-09-02668}
--------------

The study was approved by the Ethical and Clinical Research Committee of the institution (CEIC number: 2015/6012/I). Written informed consent was obtained from each subject after they received a complete description of the study and had been given the chance to discuss any questions or issues before the start. Study participants were reimbursed with 20 euros for their participation in the study. Participation in this study consisted in one visit of approximately 3 h, where participants were interviewed and blood samples were collected. Genetic samples were adequately stored under professional biobanking procedures until the end of the recruitment period and then prepared for analysis. Blood samples were analysed by the Hospital del Mar (Laboratori de Referència de Catalunya). Genetic samples were adequately stored by UPF-CompOmics under professional biobanking procedures until the end of the recruitment period. Afterwards, biological samples were provided to the Genomics Core Facility service at the National Genotyping Center (CeGen) for sample preparation. Finally, genetic data from CeGen were shared with UPF-CompOmics for analysis.

2.5. Data Analysis {#sec2dot5-jcm-09-02668}
------------------

### 2.5.1. Clinical and Blood Tests {#sec2dot5dot1-jcm-09-02668}

Analysis of clinical and blood test data were performed using SPSS Version 23 (IBM SPSS Statistics for Windows (IBM Corp., Armonk, NY, USA). Frequencies, percentages, mean and standard deviations (SD) were calculated. Analysis of the relationship between variables was performed through Chi-Square for dichotomous variables and T-Test (independent samples) for continuous variables. A 5% or lower *p*-value (i.e., \<0.05) was considered statistically significant.

### 2.5.2. Genetic Data {#sec2dot5dot2-jcm-09-02668}

-   Genotyping procedure

The protocol used in the processing of this platform is detailed in the user guide "Axiom™ 2.0 Assay Manual Workflow", available at [www.thermofisher.com](www.thermofisher.com). In summary, the total genomic DNA was amplified and fragmented up to 25--125 bp. These fragments were purified and re-suspended in the hybridization solution that was transferred to the GeneTitan Instrument to follow its fully automated processing (hybridization in the array plates, staining, washing and scanning). The raw images were automatically processed and the genotypes were obtained by applying the Axiom algorithm, available through the Axiom Analysis Suite software (version, 4.0. Affymetrix, Inc.; Santa Clara, CA, USA, [www.thermofisher.com](www.thermofisher.com)).

-   Association analysis

For the association analysis, we used a whole genome association analysis toolset called Plink. We performed 3 different tests separately: (i) basic allelic chi-square; (ii) Fisher's exact test and (iii) logistic regression to test for differences between the individuals affected by Primary MD and the individuals affected by AI-MD.

Apart from testing each single variant, a covariates analysis was also conducted into the logistic model. A total of 16 different covariates were included in the analysis, all of them related with clinical features considered relevant for depression heritability. These covariates were: gender, age, birth date, race, depression family history, alcohol family history, SUD family history, depression age of onset, severity of depression (HAM-D, BECK and SSI), anxiety scales (HAM-A, STAI-R and STAI-E), number of suicide attempts and live events scale (LSC-R).

3. Results {#sec3-jcm-09-02668}
==========

A total of 111 patients were assessed for eligibility. Twenty of them met at least one of the exclusion criteria and eleven refused to participate. A total of 80 participants were included in the study, 47 with Primary MD and 33 with an AI-MD diagnosis.

3.1. Clinical {#sec3dot1-jcm-09-02668}
-------------

Clinical results included socio-demographic/family history and the results of the different clinical scales for clinical assessment of depression severity, anxiety severity, personality and traumatic and stressful life events.

### 3.1.1. Socio-Demographic/Family History {#sec3dot1dot1-jcm-09-02668}

No significant differences were found between the two groups in terms of main sociodemographic characteristics ([Table 1](#jcm-09-02668-t001){ref-type="table"}); although, subjects with Primary MD had a higher education level in comparison with participants in the AI-MD group. Regarding medical comorbidities, a significant difference was found (*p* = 0.026) with more subjects from the AI-MD group (54.5%) reporting this condition in comparison to Primary MD participants (29.8%). The majority of comorbidities included any hepatic disease and lipid metabolism disorders.

There were no significant differences with respect to hospitalization due to medical comorbidities. Most of the participants reported to be in pharmacological treatment with antidepressants without differences between Primary MD and AI-MD group (100% vs. 96.7% respectively; *p* = 0.37). Almost 80% of Primary MD participants provided information on history of depression in family members with differences between groups (*p* = 0.042). In contrast, a higher percentage of AI-MD participants reported alcohol and substance use disorders in their family history. Fifty-three percent of AI-MD patients and 28.3% of Primary MD group of patients reported a family history of alcohol use (*p* = 0.033). Finally, differences were also found for a family history of other substance use disorders (31.3% of AI-MD vs. 8.7% Primary MD, *p* = 0.016).

### 3.1.2. Clinical Assessment {#sec3dot1dot2-jcm-09-02668}

Characteristics of AUD in the AI-MD group were collected with a PRISM interview: The mean age of onset of alcohol abuse was 33.42 years (12.26 SD) and 37.34 years (12.49 DS) for alcohol dependence. According to the DSM-IV TR diagnosis criteria, 100% of subjects fulfilled a lifetime criteria for alcohol dependence and 94% for the last 12 months. The mean age for first alcohol disorder treatment in the AI-MD patients was 37.55 years (15.96 SD).

The main results in clinical severity for depression are described in [Table 2](#jcm-09-02668-t002){ref-type="table"}. There were no differences in the age of onset of depression between the two groups. Moreover, there were no differences between groups for any of the instruments assessing the severity of depression (HAM-D, BDI and SSI) or anxiety (HAM-A and STAI). Furthermore, the severity of depression was not associated with the age of onset of alcohol addiction in the AI-MD group. A trauma and life events instrument (LSC-R) showed a higher mean score in patients with AI-MD diagnosis compared to Primary MD patients, ((14.21 ± 11.35 SD) vs. 9.30 ± 7.38 SD; *p* = 0.021)). There were no differences for the temperament and character (dimensions between groups). There were differences between groups regarding the following subscales: "disorderliness" trait from "novelty seeking" dimension (*p* = 0.035), showing AI-MD patients with higher scores in comparison to Primary MD patients (51.81 ± 10.05 and 46.29 ± 11.44, respectively). In addition, differences (*p* = 0.034) were found between groups regarding "conformity" trait from "reward dependence" dimension; patients in the Primary MD group showed a higher mean score (50.79 ± 9.41) than patients with an AI-MD diagnosis (44.87 ± 13.92).

Taking into account the DSM-IV-TR depression criteria for the diagnosis of depression, five (or more) criteria should be present during the same 2-week period and should represent a change from previous functioning; at least one of the symptoms is either: depressed mood or loss of interest or pleasure. The nine criteria are described in [Table 2](#jcm-09-02668-t002){ref-type="table"}. First, there were no differences between groups for the first criteria (depressed mood), showing both groups with a similar prevalence of these criteria (97.9% in Primary MD vs. 94.1% in AI-MD). However, differences were found for the second criteria (anhedonia). The majority of Primary MD participants (97.9%) reported this symptom while a lower number in AI-MD participants reported it (82.4%) (*p* = 0.014). There were differences in relation to the third criterion, changes in weight and/or appetite; AI-MD patients showed a higher prevalence (91.2%) than patients with primary episodes (72.3%) (*p* = 0.036). There were also differences in the eight criteria (diminished ability to concentrate), more frequent among PMD patients (97.9%) than AI-MD group of patients (79.4%) (*p* = 0.006). Finally, differences were found in recurrent thoughts of death (criteria 9), where 63.8% of PMD patients showed these criteria and 29.4% of AI-MD patients (*p* = 0.002). There were no differences in other depression criteria.

3.2. Blood Test Results {#sec3dot2-jcm-09-02668}
-----------------------

Regarding the blood test results, AI-MD participants had more significant abnormal results in comparison with Primary MD in the following: TSH (*p* = 0.016), AST (*p* \< 0.001), ALT (*p* \< 0.001), ALP (*p* = 0.043) and GGT (*p* \< 0.001). There were no significant differences in the results of CRP levels, bilirubin, cholesterol and triglycerides between groups. [Table 3](#jcm-09-02668-t003){ref-type="table"} shows the total number of participants (or percentage) with pathological results in both groups.

3.3. GWAS Results {#sec3dot3-jcm-09-02668}
-----------------

Variants with a missing rate higher than 5% or having a minor allele frequency lower than 1% or deviating significantly from Hardy--Weinberg equilibrium were filtered out. From the original 814,923 variants, 508,097 were considered for further analysis. A total of 24 samples were removed after quality control. For 16 individuals, unusual Identity By Descent (IBD) values were observed when compared to the rest of patients and were discarded due to possible contamination. An additional individual showed an heterozygosity rate deviating from the heterozygosity observed in the rest of patients. Principal component analysis (PCA) was performed to assess ancestry and seven patients with non-European ancestry were discarded for further analysis. As association analyses are generally performed considering only variants with a high frequency in the population, variants with a frequency lower than 5% in the sequenced samples were filtered out. For each single variant, among the 341,946 common variants for genotyping data, three different tests were performed separately: (i) basic allelic chi-square, (ii) Fisher's exact test and (iii) logistic regression. A Manhattan plot resulted from each test ([Figure 1](#jcm-09-02668-f001){ref-type="fig"}). For each test, we created a table that contains the odd-ratios obtained (effect of the variants) and *p*-values, for more information about this tables see [Table A1](#jcm-09-02668-t0A1){ref-type="table"}, [Table A2](#jcm-09-02668-t0A2){ref-type="table"} and [Table A3](#jcm-09-02668-t0A3){ref-type="table"}.

Apart from testing each single variant, covariates were also included into the logistic model. When including all the provided covariates into the logistic model even the most minimal differences between two groups of samples disappeared, suggesting that correcting for all these covariates jointly is not useful to identify the genetic differences between the two groups of individuals in our study. On the other hand, covariates were also analysed separately in [Figure 2](#jcm-09-02668-f002){ref-type="fig"} and none of the variants reached statistical significance.

Overall, none of the variants reached significance beyond multiple testing thresholds, although, some suggestive variants were observed in chromosomes 2, 6, 10, 13 and 19 in the basic allele chi-square test and Fisher's exact test ([Figure 2](#jcm-09-02668-f002){ref-type="fig"}).

Interestingly, variants rs3130531, rs7772901, rs73115241, rs386580033 and rs529060937 were among the top 20 variants for all the three different applied association tests; moreover 17 over the 20 SNPs listed in [Table 4](#jcm-09-02668-t004){ref-type="table"} were also represented in [Table 4](#jcm-09-02668-t004){ref-type="table"} meaning that a basic allele chi-square test and Fisher's exact test produced very similar results. Covariates analyses in a regression model did not provided any significant result. [Table 4](#jcm-09-02668-t004){ref-type="table"} shows further information of the five relevant variants.

4. Discussion {#sec4-jcm-09-02668}
=============

AI-MD is a common and clinically relevant condition that should be better characterized to improve its diagnosis and adequate treatment. This study has found clinical and biological features that may help physicians in differentiating AI-MD from primary MD and improve the knowledge about their etiopathology and also, its therapeutic approach. Clinical differences were found mainly in family history of diseases; criteria used for depression diagnosis, lifetime traumatic stressors and medical comorbidities. However, non-genetic differences were found.

AI-MD patients showed greater alcohol use and a family history of other substances use disorders, whilst in contrast, MD patients showed greater family history of depression. Interestingly, AI-MD patients showed greater lifetime stressors events such as physical abuse, childhood abuse, intimate partner violence, etc. These findings are consistent with other animal and human studies reporting an association between traumatic events and SUDs \[[@B63-jcm-09-02668],[@B64-jcm-09-02668],[@B65-jcm-09-02668],[@B66-jcm-09-02668],[@B67-jcm-09-02668]\]. Furthermore, as expected, AI-MD showed more medical comorbidity possibly by the effects related to the alcohol use, and its toxicity \[[@B68-jcm-09-02668]\]. Finally, overall, personality dimensions and traits did not show large differences between groups.

We identified some further differences in the criteria used to diagnose MD according to DSM-IV-TR \[[@B69-jcm-09-02668]\]. We only found differences in four of the nine criterions used to diagnose depression. AI-MD patients met with more frequency the criteria related to changes in weight. The high medical comorbidity found among AI-MD patients may explain this significant difference related to weight criteria \[[@B70-jcm-09-02668],[@B71-jcm-09-02668]\] although we have not detected this association in our sample. Other authors have found different criteria between Primary and Induced depression associated with cocaine use disorder \[[@B72-jcm-09-02668]\]; however, these authors found more "weight changes" in the primary depression group compared to induced depression group. In contrast, Primary MD patients met more criteria related to anhedonia, loss of concentration and recurrent thoughts of death. Our results are not according to other studies and show that depressive co-morbidity in patients with AUD may thus be characterized by more pronounced levels of anhedonia, as compared to other symptom domains of depression \[[@B73-jcm-09-02668]\]. Animal and human studies were the focus in the paper of anhedonia as a transdiagnostic symptom. Anhedonia is a core symptom in depression and it is also involved in addictive disorders \[[@B74-jcm-09-02668]\]. In this sense, dysregulation of the reward system and alterations in ventral extrapyramidal circuits were described in both disorders \[[@B75-jcm-09-02668],[@B76-jcm-09-02668]\]. These findings imply acute dysfunction within mesolimbic dopamine pathways, although the cause of such alterations is unclear \[[@B77-jcm-09-02668]\].

The differences in the blood test in terms of liver enzymes having a greater prevalence of abnormal results in the AI-MD group, in the same line as the severe medical condition, were expected due to the well recognized association between alcohol use and liver disease (for review Fuster and Samet, 2018) \[[@B78-jcm-09-02668]\], ranging from steatosis to cirrhosis and liver cancer. A relationship between liver disease, AUD and depressive symptoms has also been described \[[@B79-jcm-09-02668]\]; the underlying mechanism could be associated with inflammatory processes that are worsened by alcohol consumption \[[@B80-jcm-09-02668]\]. Finally, animal and human studies have described an association between changes in the hypothalamus--pituitary--thyroid (HPT) axis and AUD \[[@B81-jcm-09-02668]\]; these changes seems to normalize after detoxification \[[@B82-jcm-09-02668],[@B83-jcm-09-02668]\]. The mechanism that has been related with changes in TSH levels is that alcohol could affect the feedback inhibition of the thyroid hormones by having a direct toxic effect on the thyroid gland and a compensatory increase in the thyroid release hormone secretion.

Regarding GWAS findings, single variant association analysis did not produce any significant result nor when including clinical covariates (jointly, separately or combinations of them). Nevertheless, some suggestive variants were identified: 5 SNPs having the lowest P-values for the 3 types of statistical analysis were: rs3130531, rs7772901, rs73115241, rs386580033 and rs529060937. As far as we know, none of those SNPs have been previously associated to depression, nor alcohol use disorder. For the rs3130531, the T allele was more prevalent in the AI-MD group compared to Primary MD group of patients. This SNP has been implicated in somatic illness as rheumatoid arthritis \[[@B84-jcm-09-02668]\] and diabetes \[[@B85-jcm-09-02668]\], but at this moment, no association has been described previously with depression nor AUD. The rs73115241 is an intergenic variant, located in Chromosome 20 with no currently known function. The T allele was more prevalent in the AI-MD group compared to the Primary MD group. The rs7772901, is an intronic variant; in our sample, the C allele was more prevalent in the AI-MD group than in the Primary MD group of patients. Finally, rs386580033 and rs529060937 correspond both to intronic variants, probably with a regulatory function. In our sample, the A and the G allele, respectively, were more prevalent in the Primary MD group than in the AI-MD diagnosed patients.

Our findings have some limitations that should be considered. The main limitation is related to the small sample size and not having control groups to compare (healthy controls and AUD non-depressed controls). The analysis performed did not show differences in women, but this could be related with the sample size, which has made it not possible to study the effect of gender. Depressive disorders are more common in women than men, moreover, depression associated with addictive disorders (either primary or induced) is more prevalent in women with SUD than in men, and more frequent than expected in women without any SUD \[[@B86-jcm-09-02668]\]. Differences have also been found in clinical presentation and some neurobiological markers \[[@B87-jcm-09-02668]\]. A bigger sample size could help to detect gender differences. Furthermore, replication is required in an independent set of samples and/or using alternative and more complex genomic risk score methods. In addition, MD and AUD has a modest heritability, both are polygenic disorders meaning that many genetic variants have an individual small effect size. Finally, due to the effects of alcohol consumption in inflammatory pathways which also have been related with depression, it would be important to replicate these findings, comparing them with a group of AUD without any depression.

In spite of these limitations, the accurate process of phenotype and genotype of the samples is a strong point of the study. AI-MD has crucial implications for both prognosis and therapeutic approaches. In two previous meta-analyses of antidepressant treatments in comorbid depression with substance use, the lack of response to selective serotonin reuptake inhibitors (SSRIs) was explained by the possible confounding factor of the presence of substance-induced depression in the samples \[[@B17-jcm-09-02668],[@B18-jcm-09-02668]\]. In this context, the distinction between Primary MD and AI-MD might be crucial to improve treatment strategies and outcomes. To date, the diagnosis is based on clinical criteria (using DSM-5 (American Psychiatric Association 2013) or ICD-10 (Organización Mundial de la Salud 2000)) but there is still a need for specific biomarkers to facilitate the identification of AI-MD to improve diagnosis and clinical management. In this sense, genetic studies including expression studies, pharmacogenomics and epigenetics can improve the diagnosis, therapeutic approach and prognosis of these prevalent diseases.

5. Conclusions {#sec5-jcm-09-02668}
==============

This preliminary study has found clinical and biological features that may help physicians in differentiating AI-MD from primary MD. These results will facilitate future studies to increase the knowledge about their etiopathology and its therapeutic approach.
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For the purpose of this report, a table reporting those relevant differences (not achieving statistically significance) in allele frequency between the two groups were created for each test. The tables only contain those variants showing higher differences between groups. For each table we report different fields (columns) according to the specific test conducted. The psychical position (Pos) reported in the tables refers to GRCH 38 version from the Genome Reference Consortium. In [Table A1](#jcm-09-02668-t0A1){ref-type="table"}, [Table A2](#jcm-09-02668-t0A2){ref-type="table"} and [Table A3](#jcm-09-02668-t0A3){ref-type="table"} are listed the 20 SNPs showing the lowest *p*-values for basic allele chi-square test, Fisher's exact test, and logistic regression, respectively.

jcm-09-02668-t0A1_Table A1

###### 

Basic allele chi-square test.

  SNP           Chr   Pos         Effect Allele   Alternative Allele   F_AI-MD   F_Primary MD   OR       *p* Value
  ------------- ----- ----------- --------------- -------------------- --------- -------------- -------- ----------------
  rs73250026    6     165960669   G               A                    0.35      0.01429        37.15    7.991 × 10^−7^
  rs12355672    10    123921288   A               G                    0.3       0              NA       0.000001204
  rs2602186     2     159271306   A               G                    0.3421    0.01471        34.84    0.000001802
  rs2245046     19    47858424    A               G                    0.3684    0.02857        19.83    0.000002057
  rs61955462    13    21009654    A               G                    0.45      0.07143        10.64    0.000002643
  rs76785029    12    94882905    T               C                    0.3421    0.02857        17.68    0.000006816
  rs77332950    6     162137147   T               C                    0.375     0.04412        13       0.000008363
  rs11163044    1     81002495    T               C                    0.25      0              NA       0.00001147
  rs61893521    11    76392642    A               G                    0.425     0.07353        9.313    0.0000119
  rs73124405    20    20515790    T               G                    0.3421    0.0303         16.64    0.00001311
  rs10839772    11    1850324     A               G                    0.55      0.1571         6.556    0.00001524
  rs3130531     6     31206616    A               G                    0.7105    0.2794         6.33     0.00001749
  rs116179105   2     19494199    A               G                    0.2895    0.01471        27.3     0.00001855
  rs7772901     6     165959846   C               A                    0.475     0.1143         7.012    0.00002349
  rs28504201    3     58573163    A               G                    0.4       0.07143        8.667    0.00002465
  rs73115241    20    38797004    T               C                    0.425     0.08571        7.884    0.00002561
  rs386580033   6     31091163    A               G                    0.2       0.6176         0.1548   0.00002629
  rs2771040     9     108152199   G               A                    0.4737    0.1143         6.975    0.00003021
  rs529060937   6     31091197    G               A                    0.2105    0.6286         0.1576   0.00003293
  rs73485007    18    74495070    T               C                    0.2778    0.01471        25.77    0.00003323

Notes: Chr: Chromosome, SNP: SNP ID, Pos: Physical position (base-pair), F_AI_MD: Frequency of this allele in AI-MD, F_Primary MD: Frequency of this allele in Primary MD, OR: Estimated odds ratio, P: Asymptotic *p*-value for this test.
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###### 

Fisher's exact test.

  SNP           Chr   Pos         Effect Allele   Alternative Allele   F_AI-MD   F_Primary MD   OR        *p* Value
  ------------- ----- ----------- --------------- -------------------- --------- -------------- --------- -------------
  rs73250026    6     165960669   G               A                    0.35      0.01429        37.15     0.000001416
  rs12355672    10    123921288   A               G                    0.3       0              NA        0.000001588
  rs2602186     2     159271306   A               G                    0.3421    0.01471        34.84     0.000003575
  rs2245046     19    47858424    A               G                    0.3684    0.02857        19.83     0.000004805
  rs61955462    13    21009654    A               G                    0.45      0.07143        10.64     0.000005148
  rs77332950    6     162137147   T               C                    0.375     0.04412        13        0.00001555
  rs76785029    12    94882905    T               C                    0.3421    0.02857        17.68     0.00001572
  rs11163044    1     81002495    T               C                    0.25      0              NA        0.00001807
  rs386580033   6     31091163    A               G                    0.2       0.6176         0.1548    0.00002548
  rs73124405    20    20515790    T               G                    0.3421    0.0303         16.64     0.00002572
  rs10839772    11    1850324     A               G                    0.55      0.1571         6.556     0.00002733
  rs61893521    11    76392642    A               G                    0.425     0.07353        9.313     0.0000293
  rs3130531     6     31206616    A               G                    0.7105    0.2794         6.33      0.00003134
  rs137916      22    50491713    A               G                    0.025     0.3529         0.04701   0.00003637
  rs116179105   2     19494199    A               G                    0.2895    0.01471        27.3      0.00003841
  rs529060937   6     31091197    G               A                    0.2105    0.6286         0.1576    0.00004234
  rs7772901     6     165959846   C               A                    0.475     0.1143         7.012     0.00005108
  rs915476      17    32288009    C               T                    0         0.2857         0         0.00005113
  rs73115241    20    38797004    T               C                    0.425     0.08571        7.884     0.00005121
  rs17780066    13    78448090    T               C                    0.2368    0              NA        0.00005933

Notes: Chr: Chromosome, SNP: SNP ID, Pos: Physical position (base-pair), F_AI_MD: Frequency of this allele in AI-MD, F_Primary MD: Frequency of this allele in Primary MD, OR: Estimated odds ratio, P: Asymptotic *p*-value for this test.
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###### 

Logistic regression.

  SNP           Chr   Pos         Effect Allele   OR        *p* Value
  ------------- ----- ----------- --------------- --------- ------------
  rs73115241    20    38797004    T               14.1      0.00008067
  rs6028915     20    38786218    C               13.63     0.0001002
  rs9933149     16    87226206    T               0.06377   0.0001541
  rs2162380     2     64556555    A               12        0.0002039
  rs7772901     6     165959846   C               9.49      0.0002534
  rs2301584     22    51171497    A               11.89     0.0003368
  rs4876226     8     2059004     T               9.259     0.0004704
  rs4876226     8     2059004     T               9.259     0.0004704
  rs4876226     8     2059004     T               9.259     0.0004704
  rs16843122    3     135278749   C               0.08456   0.0005255
  rs4765145     12    124843104   C               0.05933   0.0005727
  rs3130531     6     31206616    A               5.473     0.0005918
  rs386580033   6     31091163    A               0.1706    0.0006138
  rs7407243     18    70010868    G               9.425     0.000684
  rs529060937   6     31091197    G               0.1759    0.0007074
  rs4913427     12    68631620    T               0.1561    0.0007113
  rs499691      6     32194339    T               7.06      0.0007266
  rs1048677     17    3564716     G               7.575     0.0007284
  rs6046396     20    19852503    G               6.717     0.0007339
  rs34058147    13    75567543    G               0.1383    0.0007866

Notes: Chr: Chromosome, SNP: SNP ID, Pos: Physical position (base-pair), F_AI_MD: Frequency of this allele in AI-MD, F_Primary MD: Frequency of this allele in Primary MD, OR: Estimated odds ratio, P: Asymptotic *p*-value for this test.
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###### 

Sociodemographic and family history data.

  Sample Characteristics           Primary MD      AI-MD          *p* ^a^
  -------------------------------- --------------- -------------- -----------
  Age (Mean ± SD)                  49.87 ± 11.32   50.39 ± 8.89   0.140 ^b^
  Gender                                                          0.678
  Men                              22 (46.8)       17 (51.5)      
  Women                            25 (53.2)       16 (48.5)      
  Household structure                                             0.736
  Alone                            14 (29.8)       11(33.3)       
  With others                      33 (70.2)       22(66.7)       
  Education level                                                 0.041
  Primary or Secondary education   20 (42.6)       21 (65.6)      
  Upper secondary education        27(57.4)        11 (34.4)      
  Employment situation                                            0.271
  Employed                         16 (34)         6 (18.8)       
  Unemployed                       1 (2.1)         0              
  Disability                       27 (57.4)       25 (78.1)      
  Retired                          3 (6.4)         1 (3.1)        
  Medical comorbidities                                           
  Serious illness (SI)             14 (29.8)       18 (54.5)      0.026 \*
  Hospitalization due to SI ^c^    14 (100)        17 (94.4)      0.370
  Current medication ^d^           46 (100)        29 (96.7)      0.213
  Family History                                                  
  Depression ^e^                   35(79.5)        17(56.7)       0.042 \*
  Alcohol use disorder ^f^         13 (28.3)       16(53.3)       0.033 \*
  Substance use disorder ^g^       4 (8.7)         10(31.3)       0.016 \*

Notes: ^a^ Chi-Square; ^b^ Student's T-Test; ^c^ n = 32; ^d^ n = 76; ^e^ n = 74; ^f^ n = 76; ^g^ n = 78; \* Significance (*p* \< 0.05). MD: Major Depression; AI-MD: Alcohol Induced Major Depression.
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###### 

Results of Clinical Assessment on depression, anxiety, personality and stressful events.

  Variables                                                   Primary MD      AI-MD           *p* ^a^
  ----------------------------------------------------------- --------------- --------------- ----------
  Age onset depression (years)                                37.64 (13.53)   39.18 (11.26)   0.593
  HAM-D                                                       15.64 ± 10.34   11.88 ± 7.54    0.79
  BDI                                                         22.37 ± 14.65   23.41 ± 11.59   0.739
  SSI                                                         11.68 ± 8.12    12.36 ± 8.48    0.156
  HAM-A                                                       25.22 ± 14.32   25.67 ± 12      0.884
  STAI                                                                                        
  STAI- State                                                 28.17± 13.82    27.44 ± 13.78   0.817
  STAI- Trait                                                 30.00 ± 13.16   32.28 ± 11.17   0.425
  LSC-R                                                       9.30 (7.38)     14.21 (11.35)   0.021 \*
  Personality Dimensions                                                                      
  *Temperament*                                                                               
  Novelty seeking (NS)                                        47.38± 11.07    50.84 ± 9.89    0.172
  Harm avoidance (HA)                                         54.60 ± 11.82   60.87 ± 11.61   0.415
  Reward dependence (RD)                                      43.57 ± 9.65    45.68 ± 10.66   0.381
  Persistence (PS)                                            44.45 ± 9.92    47.55 ± 11.62   0.224
  *Character*                                                                                 
  Self-directedness (SD)                                      42.33 ± 11.92   39.61 ± 11.12   0.325
  Cooperativeness (CO)                                        45.14 ± 11.42   45 ± 12.22      0.959
  Self-transcendence (ST)                                     48.74 ± 10.57   50.35 ± 11.53   0.536
  Depression Criteria                                                                         
  Criteria 1: depressed mood                                  46 (97.9)       32 (94.1)       0.377
  Criteria 2: diminished interest or pleasure                 46 (97.9)       28 (82.4)       0.014 \*
  Criteria 3: significant unintentional weight loss or gain   34 (72.3)       31 (91.2)       0.036 \*
  Criteria 4: insomnia or sleeping too much                   43 (91.5)       27 (79.4)       0.117
  Criteria 5: agitation or psychomotor retardation            34 (72.3)       22 (64.7)       0.463
  Criteria 6: fatigue                                         44 (93.6)       27 (79.4)       0.055
  Criteria 7 feelings of worthlessness or excessive guilt     43 (91.5)       28 (82.4)       0.217
  Criteria 8: diminished ability to think or concentrate      46 (97.9)       27 (79.4)       0.006 \*
  Criteria 9: recurrent thoughts of death                     30 (63.8)       10 (29.4)       0.002 \*

Notes: ^a^ Student's T-Test \* Significance (*p* \< 0.05). HAM-D: Hamilton Depression Rating Scale, BDI: Beck Depression Inventory, SSI: Suicidal Ideation Scale, HAM-A: Hamilton Anxiety Rating Scale, STAI: State-Trait Anxiety Inventory, LSC-R: Life Stressor Checklist-Revised.
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###### 

Results of pathological blood test in Primary MD and AI-MD groups.

  --------------------------------------------------------------------------------------
  Biochemical Paramaters   Subjects with Abnormal Values \*   *p*         
  ------------------------ ---------------------------------- ----------- --------------
  TSH ^a^\                 0                                  4 (12.5)    0.016 \*\*
  (10--38 mcUI/mL)                                                        

  Bilirubin ^b^\           2 (5)                              4 (12.1)    0.270
  (0.2--1.2 mg/dL)                                                        

  AST ^c^ (UI/L)\          4 (9.3)                            17 (51.5)   \<0.001 \*\*
  10--38 UI/L                                                             

  ALT ^d^ (UI/L)\          14 (32.6)                          26 (76.5)   \<0.001 \*\*
  7--41 UI/L                                                              

  ALP ^e^\                 3 (8.6)                            9 (27.3)    0.043 \*\*
  (40--129 UI/L)                                                          

  GGT ^f^\                 11 (32.4)                          26 (78.8)   \<0.001 \*\*
  (8--61 UI/L)                                                            

  Cholesterol ^g^\         25 (59.5)                          16 (48.5)   0.340
  (50--129 mg/dL)                                                         

  Triglycerides ^h^\       14 (33.3)                          7 (21.9)    0.279
  (40--150 mg/dL)                                                         

  CRP ^i^\                 13 (31.7)                          15 (57.7)   0.378
  (0--0.8 mg/dL)                                                          
  --------------------------------------------------------------------------------------

Notes: ^a^ Chi-Square. \* There were no patients with values below the lower range in all the parameters analysed. The parameters were considered abnormal when the value was above the highest range; \*\* Significance (*p* \< 0.05), Thyroid-stimulating hormone (TSH), alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transpeptidase (GGT), C Reactive Protein (CRP). ^a^ n = 76, ^b^ n = 73, ^c^ n = 76, ^d^ n = 77, ^e^ n = 68, ^f^ n = 67, ^g^ n = 74, ^h^ n = 74, ^i^ n = 67.
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###### 

Genetic information of the five relevant variants.

  SNP           Gene       Function         Probeset ID   Genotype Category
  ------------- ---------- ---------------- ------------- --------------------
  rs3130531                intergenic       AX-11435435   PolyHighResolution
  rs7772901     PDE10A     intron variant   AX-11644567   PolyHighResolution
  rs73115241               intergenic       AX-13511810   PolyHighResolution
  rs386580033   PSORS1C1   intron variant   AX-35729741   PolyHighResolution
  rs529060937   PSORS1C1   intron variant   AX-35729743   PolyHighResolution
